Screener
Stoke Therapeutics, Inc. STOK Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,240,347 and 58,921,999 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 6 | 5 |
| Additional paid-in capital | 942,704 | 849,624 |
| Accumulated other comprehensive (loss) income | (115) | 543 |
| Accumulated deficit | (547,718) | (497,715) |
| Total stockholders’ equity | $394,877 | $352,457 |
| Total liabilities and stockholders’ equity | $443,277 | $418,434 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s total equity?
- Stoke Therapeutics, Inc. (STOK) reported total equity of $394.88M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s total equity changed year-over-year?
- Stoke Therapeutics, Inc.'s total equity increased by 12.8% year-over-year, from $350.07M to $394.88M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s total equity has grown at a 4.3% compound annual growth rate (CAGR), from $286.08M to $352.46M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Stoke Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude